🔎 Trials Near Me

Početna › Ulcerativni kolitis › Maryland

Kliničke studije za Ulcerativni kolitis u državi Maryland

13 studija za Ulcerativni kolitis traži sudionike na lokacijama u državi Maryland.

Gradovi u državi Maryland

Službeni tekst studije (engleski)

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

  • National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaOpažajna studija
Od 18 do 85 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07619547

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Capital Digestive Care, Chevy Chase
  • Woodholme Gastroenterology, Glen Burnie
U tijeku regrutacijaFaza 4
Od 18 do 80 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT06581328

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  • Site 011, Glen Burnie
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT07012395

Immune Regulation in Ulcerative Colitis or Crohn s Disease

  • National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
1 Day – 75 Years · Oba spola · Ažurirano 28. ruj 2026. · NCT00001184

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  • Chevy Chase Clinical Research, Chevy Chase
  • Woodholme Gastroenterology Associates, Glen Burnie
U tijeku regrutacijaFaza 3
Od 12 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07196748

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Capital Digestive Care - Chevy Chase, Chevy Chase
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT03816345

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase
U tijeku regrutacijaFaza 4
Od 18 do 65 godina · Oba spola · Ažurirano 21. ruj 2026. · NCT06095128

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Mercy Medical Center, Baltimore - Site Number: 8400117, Baltimore
  • Mid-Atlantic GI Research, LLC - Site Number: 8400106, Greenbelt
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 20. kol 2026. · NCT07184996

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • Mercy Medical Center, Baltimore
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT07237516

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  • MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase
  • Woodholme Gastroenterology Associates PA, Glen Burnie
U tijeku regrutacijaOpažajna studija
Od 18 do 64 godina · Oba spola · Ažurirano 9. srp 2026. · NCT06398626

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  • Woodholme Gastroenterology Associates, Glen Burnie
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. svi 2026. · NCT06764615

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

  • Capital Digestive Care, Chevy Chase
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 8. svi 2025. · NCT06750731

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.